Skip to main content

Advertisement

Table 1 Demographic and clinicopathologic characteristics of the 111 unselected patients with endometrial cancer

From: Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China

Characteristic Total Germline MMR gene mutation IHC MMR protein MSI
Absence Presence p value Intact Deficient p value Negative Positive p value
Total (cases) 111 105 6   74 28   71 12  
Age (years; median [range])   56.00 (31–82) 54.00 (48–57) 0.440 56.50 (32–82) 53.50 (31–73) 0.102 57.00 (32–82) 55.00 (40–73) 0.658
Gravidity [median (range)]   2 (0–7) 2 (0–5) 0.374 2 (0–5) 2 (0–7) 0.437 2 (0–7) 2 (0–5) 0.020
Parity (median, range)   1 (0–4) 1 (0–2) 0.779 1 (0–4) 1 (0–2) 0.498 1 (0–4) 1 (0–3) 0.189
BMI (kg/m2; median [range])   24.98 (19–32) 21.60 (19–23) 0.010 25.66 (19–32) 24.27 (20–32) 0.622 24.98 (19–32) 23.87 (19–31) 0.343
Involvement of the lower uterine segment [cases (%)] 27 24 (22.9) 3 (50.0) 0.132 17 (23.0) 9 (32.1) 0.343 14 (19.7) 4 (33.3) 0.290
Type of EC [cases (%)]     0.189    0.983    0.937
 Type I 87 81 (77.1) 6 (100.0)   58 (78.4) 22 (78.6)   54 (76.1) 9 (75.0)  
 Type IIa 24 24 (22.9) 0 (0)   16 (21.6) 6 (21.4)   17 (23.9) 3 (25.0)  
FIGO stage [cases (%)]b     0.012    0.266    0.354
 FIGO I 87 85 (81.0) 2 (33.3)   61 (82.4) 19 (67.9)   60 (84.5) 9 (75.0)  
 FIGO III 19 15 (14.3) 4 (66.7)   11 (14.9) 8 (28.6)   8 (11.3) 3 (25.0)  
 FIGO IV 4 4 (3.8) 0 (0)   2 (2.7) 1 (3.6)   3 (4.2) 0 (0)  
 Unknown 1 1 (1.0) 0 (0)   0 (0) 0 (0)   0 (0) 0 (0)  
  1. Italic values indicate significance of p value (p < 0.05)
  2. MMR: mismatch repair; IHC: immunohistochemistry; MSI: microsatellite instability; SD: standard deviation; BMI: body mass index; EC: endometrial carcinoma; FIGO: International Federation of Gynecology and Obstetrics
  3. aAmong 24 cases of type II endometrial cancer, there were nine cases of the serous subtype, three of clear cell carcinoma, four of carcinosarcoma, one of undifferentiated carcinoma, and seven cases of mixed carcinoma (four cases of endometrioid and clear cell carcinomas, two cases of the endometrioid and serous subtypes, and one case of endometrioid subtype and carcinosarcoma)
  4. bNo patients had FIGO II disease